Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FQQB0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $15,792
Award facts
- Contract value 100% obligated
- $15,792.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $15,792.20 to DMS Pharmaceutical Group Inc. on January 9, 2026, for the supply of Xolair 150 mg/ml syringes. The order, which carries a firm fixed-price structure with no set-aside designation, is scheduled for ultimate completion on February 2, 2026, and will be fulfilled at the vendor's location in Park Ridge, Illinois. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler that has maintained active registration in the System for Award Management since 2001 and specializes in distributing pharmaceutical products and medical consumables to federal agencies, particularly the Department of Defense.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to support recurring medical supply needs for military healthcare facilities worldwide. The parent contract, designated SPE2DR and valued at $499,999,999, was awarded on November 13, 2025, with completion scheduled for December 31, 2036. The vendor's established performance across multiple delivery orders demonstrates its capability to fulfill the diverse and specialized pharmaceutical requirements of Department of Defense healthcare operations globally, with products including both branded and generic pharmaceuticals, biologics, and specialty medical consumables.
Quick answers
Who was awarded contract SPE2DR26FQQB0?
SPE2DR26FQQB0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 9, 2026.
How much is contract SPE2DR26FQQB0 worth?
The government has obligated $15,792 on SPE2DR26FQQB0.
Is contract SPE2DR26FQQB0 an order under another contract?
Yes. SPE2DR26FQQB0 is a delivery order under SPE2DR25D9331, an indefinite delivery contract.
Was contract SPE2DR26FQQB0 competed?
The extent of competition for SPE2DR26FQQB0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award